Director, Molecular Pathology, Translational Sciences, Translational Research

Overview

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.

As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

The Opportunity

As a Director, Molecular Pathology, you will be a key member of a cross-functional Translational Sciences Team, reporting to the Senior Director and Head of Translational Sciences within Translational Research and will:

• Biomarker Strategy:
  Define and execute molecular and digital pathology-driven biomarker strategies.
• Integration of Advanced Modalities:
  Lead adoption of molecular pathology and spatial technologies (to support translational research and broader BDR needs).
• Digital & Computational Pathology:
  Drive implementation of whole-slide imaging, AI/ML-based image analysis, and integration of spatial biomarker analytics into decision-making.
• Data Interpretation & Reporting:
  Provide expert interpretation of pathology data, ensuring robust correlation with clinical outcomes and mechanistic insights.
• Cross-functional Leadership:
  Collaborate with Translational Medicine, Bioinformatics, and Clinical Development colleagues to implement candidate biomarkers into Translational Biomarker plans for RAS(ON) inhibitors in alignment with overarching clinical development strategies.

• Scientific Leadership & Execution:
  Perform and interpret multiplex spatial biomarker datasets to inform Translational hypotheses and clinical strategies. Establish QC standards for data acquisition and analysis.
• Cross-Functional Collaboration:
  
  Partner within Research and Clinical teams to integrate spatial biomarker findings into translational plans. Collaborate with Systems Biology and Information Sciences teams to enable visualization tools.
• External Partnership Management:
  Serve as primary scientific liaison to CROs for spatial biomarker workflows; review deliverables, troubleshoot issues, and drive continuous improvement.
• Capability Building:
  Document best practices and SOPs for spatial biomarker workflows; recommend platform upgrades and pilot evaluations.

• 10+ years in digital pathology/spatial biology within pharma, biotech, or CRO settings.
• Scientific Expertise:
  Deep knowledge of spatial biology (e.g. spatial transcriptomics, Visium, Xenium, Geo Mx, Mer Fish, etc.); ability to translate complex data into actionable insights.
• Execution Excellence:
  Bias for action; delivers high-quality analyses under tight timelines.
• Collaboration & Influence:
  Builds strong relationships across functions and with external partners; communicates clearly and persuasively.
• Innovation & Continuous Improvement:
  Identifies opportunities to enhance workflows and adopt emerging technologies.
• PhD/MD or equivalent in Cancer Biology, Translational Sciences, Pathology or related discipline.

• Hands-on experience with spatial pathology workloads.
• Familiarity with AI/ML-assisted pathology workflows and spatial statistics.
• Proven ability to manage CRO relationships and deliver time-sensitive biomarker analyses.

The base pay salary range for this full-time position for candidates working onsite at our headquarters in…